A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

PURPOSE: Bevacizumab is an antibody against vascular endothelial growth factor (VEGF); sunitinib is an inhibitor of VEGF and related receptors. The safety and maximum tolerated dose (MTD) of sunitinib plus bevacizumab was assessed in this phase I trial. EXPERIMENTAL DESIGN: Patients with advanced so...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rini, Brian I., Garcia, Jorge A., Cooney, Matthew M., Elson, Paul, Tyler, Allison, Beatty, Kristi, Bokar, Joseph, Mekhail, Tarek, Bukowski, R.M., Budd, G. Thomas, Triozzi, Pierre, Borden, Ernest, Ivy, Percy, Chen, Helen X., Dolwati, Afshin, Dreicer, Robert
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2756318/
https://ncbi.nlm.nih.gov/pubmed/19773375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0717
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller